

Andre C Kalil

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5501427/publications.pdf>

Version: 2024-02-01

207
papers

18,859
citations

31976

53
h-index

12946

131
g-index

207
all docs

207
docs citations

207
times ranked

28358
citing authors

#	ARTICLE	IF	CITATIONS
1	Molnupiravir: Is It Time to Move In or Move Out?. , 2022, 1, .		5
2	The Potential for Increasing Risk of Consent Refusal in COVID-19 Trials: Considering Underlying Reasons and Responses. Annals of the American Thoracic Society, 2022, 19, 1446-1447.	3.2	4
3	Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial. Lancet Respiratory Medicine,the, 2022, 10, 888-899.	10.7	62
4	From Syphilis to Sepsis: Pilot Studies and the Importance of Staying Grounded*. Critical Care Medicine, 2022, 50, 1015-1018.	0.9	0
5	Lower Respiratory Tract Coinfection in the ICU: Prevalence and Clinical Significance of Coinfection Detected via Microbiological Analysis of Bronchoalveolar Lavage Fluid With a Comparison of Invasive Methodologies. , 2022, 4, e0708.		0
6	A Sepsis Screening Tool for Hematopoietic Cell Transplant Recipients Remains Elusive. Clinical Infectious Diseases, 2021, 72, 1230-1231.	5.8	1
7	Infectious Diseases Society of America Position Paper: Recommended Revisions to the National Severe Sepsis and Septic Shock Early Management Bundle (SEP-1) Sepsis Quality Measure. Clinical Infectious Diseases, 2021, 72, 541-552.	5.8	103
8	American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 3. Arthritis and Rheumatology, 2021, 73, e1-e12.	5.6	201
9	Strategies for implementation of a multidisciplinary approach to the treatment of nosocomial infections in critically ill patients. Expert Review of Anti-Infective Therapy, 2021, 19, 759-767.	4.4	3
10	Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. New England Journal of Medicine, 2021, 384, 795-807.	27.0	1,398
11	Opportunistic Infections After Induction With Alemtuzumab or Basiliximab: A 3-Year Kidney Transplantation Experience. Transplantation Proceedings, 2021, 53, 1058-1063.	0.6	2
12	Carbapenem Antibiotics for the Empiric Treatment of Nosocomial Pneumonia. Chest, 2021, 159, 1041-1054.	0.8	11
13	Clinical course and outcomes of critically ill patients with COVID-19 infection: a systematic review. Clinical Microbiology and Infection, 2021, 27, 47-54.	6.0	88
14	Strength of Recommendation and Quality of Evidence for Recommendations in Current Infectious Diseases Society of America Guidelines. Open Forum Infectious Diseases, 2021, 8, ofab033.	0.9	10
15	Convalescent Plasma and Coronavirus Disease 2019: Time for Reassessment*. Critical Care Medicine, 2021, 49, 1182-1186.	0.9	3
16	Risk of COVID-19 in Rheumatoid Arthritis: A National Veterans Affairs Matched Cohort Study in At-Risk Individuals. Arthritis and Rheumatology, 2021, 73, 2179-2188.	5.6	89
17	Performance Analysis of the National Early Warning Score and Modified Early Warning Score in the Adaptive COVID-19 Treatment Trial Cohort. , 2021, 3, e0474.		11
18	Editorial: COVID-19: A New Severe Infection. Current Opinion in Critical Care, 2021, 27, 461.	3.2	0

#	ARTICLE	IF	CITATIONS
19	Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors in COVID-19: Meta-analysis/Meta-regression Adjusted for Confounding Factors. <i>CJC Open</i> , 2021, 3, 965-975.	1.5	15
20	Do not just sit there, do something â€¦ but do no harm: the worrying aspects of COVID-19 experimental interventions. <i>Intensive Care Medicine</i> , 2021, 47, 896-898.	8.2	6
21	Janus Kinase inhibitors for the treatment of hospitalized patients with COVID-19. <i>Current Opinion in Critical Care</i> , 2021, 27, 493-496.	3.2	15
22	Survival Outcome of Sepsis in Recipients of Solid Organ Transplant. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2021, 42, 717-725.	2.1	3
23	Sepsis and Septic Shock. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2021, 42, 639-640.	2.1	2
24	Baricitinib: the first immunomodulatory treatment to reduce COVID-19 mortality in a placebo-controlled trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 1349-1351.	10.7	28
25	Repurposed drugs for COVID-19: threshold and proof requirements for trials. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1716-1717.	6.0	3
26	Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 1365-1376.	10.7	119
27	Mortality in Solid Organ Transplant Recipients Hospitalized for Covid-19. <i>American Journal of Transplantation</i> , 2021, 22, 12.	4.7	4
28	Is Ventilator-Associated Pneumonia More Frequent in Patients With Coronavirus Disease 2019?. <i>Critical Care Medicine</i> , 2021, Publish Ahead of Print, .	0.9	5
29	The last breath for inhaled antibiotics and VAP? Not so fast. <i>Lancet Infectious Diseases</i> , 2020, 20, 265-266.	9.1	7
30	Less is more: critically ill status is not a carte blanche for unlimited antibiotic use. <i>Intensive Care Medicine</i> , 2020, 46, 2075-2078.	8.2	2
31	Sepsis in Immunocompromised Patients Without Human Immunodeficiency Virus. <i>Journal of Infectious Diseases</i> , 2020, 222, S156-S165.	4.0	18
32	American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 2. <i>Arthritis and Rheumatology</i> , 2020, 72, e1-e12.	5.6	64
33	Response. <i>Chest</i> , 2020, 158, 2232.	0.8	0
34	Long-term consequences of COVID-19: research needs. <i>Lancet Infectious Diseases</i> , 2020, 20, 1115-1117.	9.1	241
35	Need for Additional Trials of Vitamin C for Sepsisâ€”Reply. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 608.	7.4	0
36	Chicken Soup in the Time of COVID. <i>Chest</i> , 2020, 158, 864-865.	0.8	12

#	ARTICLE	IF	CITATIONS
37	Procalcitonin Predicts the Severity of Cystic Fibrosis Pulmonary Exacerbations and Readmissions in Adult Patients: A Prospective Cohort Study. <i>Journal of Investigative Medicine</i> , 2020, 68, 856-863.	1.6	5
38	Treating COVID-19—Off-Label Drug Use, Compassionate Use, and Randomized Clinical Trials During Pandemics. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 1897.	7.4	396
39	Lack of Benefit of High-Dose Vitamin C, Thiamine, and Hydrocortisone Combination for Patients With Sepsis. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 419.	7.4	14
40	American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 1. <i>Arthritis and Rheumatology</i> , 2020, 72, 1241-1251.	5.6	142
41	Any Role for Biomarker-Guide Algorithms in Antibiotic Stewardship Programs?*. <i>Critical Care Medicine</i> , 2020, 48, 775-777.	0.9	5
42	Remdesivir for the Treatment of Covid-19 — Final Report. <i>New England Journal of Medicine</i> , 2020, 383, 1813-1826.	27.0	5,834
43	Advanced Preparation Makes Research in Emergencies and Isolation Care Possible: The Case of Novel Coronavirus Disease (COVID-19). <i>American Journal of Tropical Medicine and Hygiene</i> , 2020, 102, 926-931.	1.4	11
44	1487. Pneumonia due to Co-Infection in the ICU: Detection and Clinical Significance. <i>Open Forum Infectious Diseases</i> , 2020, 7, S745-S746.	0.9	0
45	Reply to Al-Hasan and Justo. <i>Clinical Infectious Diseases</i> , 2019, 68, 1432-1432.	5.8	2
46	Quick Sequential Organ Failure Assessment Is Not Good for Ruling Sepsis In or Out. <i>Chest</i> , 2019, 156, 197-199.	0.8	11
47	Influenza virus-related critical illness: pathophysiology and epidemiology. <i>Critical Care</i> , 2019, 23, 258.	5.8	286
48	Changes in lung microbiome do not explain the development of ventilator-associated pneumonia. <i>Intensive Care Medicine</i> , 2019, 45, 1133-1135.	8.2	10
49	Controversies in Nosocomial pneumonias in 2019. <i>Clinical Microbiology and Infection</i> , 2019, 25, 1171-1172.	6.0	0
50	Is Daptomycin plus Ceftaroline Associated with Better Clinical Outcomes than Standard of Care Monotherapy for Staphylococcus aureus Bacteremia?. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	9
51	Can ceftolozane—tazobactam treat nosocomial pneumonia?. <i>Lancet Infectious Diseases</i> , The, 2019, 19, 1266-1267.	9.1	2
52	Serious infection risk in rheumatoid arthritis compared with non-inflammatory rheumatic and musculoskeletal diseases: a US national cohort study. <i>RMD Open</i> , 2019, 5, e000935.	3.8	92
53	To Procalcitonin, or Not to Procalcitonin?. <i>Chest</i> , 2019, 155, 1085-1087.	0.8	6
54	Diagnostic and therapeutic approach to infectious diseases in solid organ transplant recipients. <i>Intensive Care Medicine</i> , 2019, 45, 573-591.	8.2	48

#	ARTICLE	IF	CITATIONS
55	New filovirus disease classification and nomenclature. <i>Nature Reviews Microbiology</i> , 2019, 17, 261-263.	28.6	84
56	O-GlcNAc Transferase Suppresses Inflammation and Necroptosis by Targeting Receptor-Interacting Serine/Threonine-Protein Kinase 3. <i>Immunity</i> , 2019, 50, 576-590.e6.	14.3	111
57	2128. Murine Typhus and Pregnancy: Case Series and Literature Review. <i>Open Forum Infectious Diseases</i> , 2019, 6, S720-S721.	0.9	0
58	2204. Microbiology of Pneumonia Due to Co-Infection in the ICU: Impact of Host Immune Status. <i>Open Forum Infectious Diseases</i> , 2019, 6, S751-S752.	0.9	0
59	2216. Pneumonia in the ICU: Epidemiology and Outcomes. <i>Open Forum Infectious Diseases</i> , 2019, 6, S756-S756.	0.9	0
60	Saved From Sepsis. <i>Critical Care Medicine</i> , 2019, 47, 733-735.	0.9	1
61	Is Procalcitonin-Guided Therapy Associated With Beneficial Outcomes in Critically Ill Patients With Sepsis?*. <i>Critical Care Medicine</i> , 2018, 46, 811-812.	0.9	2
62	Infectious Diseases Society of America (IDSA) POSITION STATEMENT: Why IDSA Did Not Endorse the Surviving Sepsis Campaign Guidelines. <i>Clinical Infectious Diseases</i> , 2018, 66, 1631-1635.	5.8	132
63	Should We Manage All Septic Patients Based on a Single Definition? An Alternative Approach. <i>Critical Care Medicine</i> , 2018, 46, 177-180.	0.9	11
64	Ceftazidime-avibactam versus meropenem for the treatment of nosocomial pneumonia. <i>Lancet Infectious Diseases</i> , The, 2018, 18, 229-231.	9.1	5
65	Ebola virus disease: an update on post-exposure prophylaxis. <i>Lancet Infectious Diseases</i> , The, 2018, 18, e183-e192.	9.1	112
66	Hospital Course after TAH Implantation, Nebraska Experience. <i>Transplantation</i> , 2018, 102, S676.	1.0	0
67	Management of Ventilator-Associated Pneumonia. <i>Clinics in Chest Medicine</i> , 2018, 39, 797-808.	2.1	24
68	Toward a More Nuanced Approach to the Early Administration of Intravenous Fluids in Patients With Sepsis. <i>JAMA Network Open</i> , 2018, 1, e185844.	5.9	5
69	Didnâ€™t inhale? Time to reconsider aerosolized antibiotics in the treatment of ventilator-associated pneumonia. <i>Critical Care</i> , 2018, 22, 333.	5.8	1
70	What Is the Best Treatment for Vancomycin-Resistant Enterococcal Bloodstream Infections?*. <i>Critical Care Medicine</i> , 2018, 46, 1700-1703.	0.9	5
71	Severe infections in critically ill solid organ transplant recipients. <i>Clinical Microbiology and Infection</i> , 2018, 24, 1257-1263.	6.0	23
72	Rethinking Ventilator Bundles*. <i>Critical Care Medicine</i> , 2018, 46, 1201-1203.	0.9	10

#	ARTICLE	IF	CITATIONS
73	Are there more differences or similarities between the hospital-acquired pneumonia guidelines?. <i>Annals of Translational Medicine</i> , 2018, 6, 429-429.	1.7	2
74	Letter to the editor: "challenges and opportunities in the treatment of ventilator-associated pneumonia"™. <i>Expert Review of Anti-Infective Therapy</i> , 2017, 15, 191-192.	4.4	0
75	Viral and bacterial co-infection in pneumonia: do we know enough to improve clinical care?. <i>Critical Care</i> , 2017, 21, 19.	5.8	7
76	Reply to Hassoun et al. <i>Clinical Infectious Diseases</i> , 2017, 64, 1633-1634.	5.8	0
77	Respiratory pathogen panels in the hospital: good or unnecessary?. <i>Current Opinion in Infectious Diseases</i> , 2017, 30, 226-230.	3.1	4
78	Clinical failure with and without empiric atypical bacteria coverage in hospitalized adults with community-acquired pneumonia: a systematic review and meta-analysis. <i>BMC Infectious Diseases</i> , 2017, 17, 385.	2.9	26
79	Colouring outside the guidelines. <i>Clinical Microbiology and Infection</i> , 2017, 23, 691-692.	6.0	2
80	Early Goal-Directed Therapy for Sepsis: A Novel Solution for Discordant Survival Outcomes in Clinical Trials. <i>Critical Care Medicine</i> , 2017, 45, 607-614.	0.9	97
81	New guidelines for nosocomial pneumonia. <i>Current Opinion in Pulmonary Medicine</i> , 2017, 23, 211-217.	2.6	16
82	Emergence of Extended-Spectrum Beta-Lactamase"Producing Enterobacteriaceae Colonization. <i>Critical Care Medicine</i> , 2017, 45, 752-754.	0.9	2
83	Clinical presentation and outcomes of norovirus infection in intestinal allograft compared to native intestine. <i>Transplant Infectious Disease</i> , 2017, 19, e12692.	1.7	3
84	Response to Letter to the Editor regarding "Incidence of ventilator associated pneumonia in burn patients with inhalation injury treated with high frequency percussive ventilation versus volume control ventilation: A systematic review". <i>Burns</i> , 2017, 43, 689-690.	1.9	0
85	Antibiotic Combination Therapy for Patients With Gram-Negative Septic Shock. <i>Critical Care Medicine</i> , 2017, 45, 1933-1936.	0.9	11
86	Vitamin C Is Not Ready for Prime Time in Sepsis but a Solution Is Close. <i>Chest</i> , 2017, 152, 676.	0.8	5
87	Is Early Goal-Directed Therapy Harmful to Patients With Sepsis and High Disease Severity?. <i>Critical Care Medicine</i> , 2017, 45, 1265-1267.	0.9	11
88	How to translate the new hospital-acquired and ventilator-associated pneumonia guideline to the bedside. <i>Current Opinion in Critical Care</i> , 2017, 23, 355-363.	3.2	1
89	Pneumonia with bacterial and viral coinfection. <i>Current Opinion in Critical Care</i> , 2017, 23, 385-390.	3.2	66
90	Sepsis and Challenging Infections in the Immunosuppressed Patient in the Intensive Care Unit. <i>Infectious Disease Clinics of North America</i> , 2017, 31, 415-434.	5.1	14

#	ARTICLE	IF	CITATIONS
91	Reply to Daniels et al.. Clinical Infectious Diseases, 2017, 64, 387-388.	5.8	0
92	Risk Factors for Development of Cytomegalovirus Resistance in Solid Organ Transplantation: A Retrospective Nested Case-Control Study. Open Forum Infectious Diseases, 2017, 4, S732-S732.	0.9	0
93	Molecular Targets for Therapy. Respiratory Medicine, 2017, , 89-104.	0.1	0
94	Risk Factors Associated with Adenovirus Infection in Solid Organ Transplant Recipients. Open Forum Infectious Diseases, 2016, 3, .	0.9	0
95	The authors reply. Critical Care Medicine, 2016, 44, e447-e448.	0.9	1
96	Incidence of ventilator associated pneumonia in burn patients with inhalation injury treated with high frequency percussive ventilation versus volume control ventilation: A systematic review. Burns, 2016, 42, 1193-1200.	1.9	20
97	Executive Summary: Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clinical Infectious Diseases, 2016, 63, 575-582.	5.8	334
98	Secondary Infection in Patients With Sepsis. JAMA - Journal of the American Medical Association, 2016, 316, 771.	7.4	1
99	Predictors of persistent diarrhea in norovirus enteritis after solid organ transplantation. Clinical Transplantation, 2016, 30, 1488-1493.	1.6	22
100	Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clinical Infectious Diseases, 2016, 63, e61-e111.	5.8	2,405
101	Risk Factors for Clostridium difficile Infection (CDI) in Intestinal Transplant Recipients (ITR) during the First Year Post-Transplant.. Open Forum Infectious Diseases, 2016, 3, .	0.9	0
102	Lessons Learned. Critical Care Medicine, 2015, 43, 1157-1164.	0.9	49
103	The use and value of procalcitonin in solid organ transplantation. Clinical Transplantation, 2015, 29, 689-696.	1.6	35
104	Critical Care for Multiple Organ Failure Secondary to Ebola Virus Disease in the United States*. Critical Care Medicine, 2015, 43, 2066-2075.	0.9	30
105	A Randomized 2x2 Factorial Clinical Trial of Renal Transplantation: Steroid-Free Maintenance Immunosuppression with Calcineurin Inhibitor Withdrawal after Six Months Associates with Improved Renal Function and Reduced Chronic Histopathology. PLoS ONE, 2015, 10, e0139247.	2.5	6
106	A Randomized 2x2 Factorial Trial, Part 1. Transplantation, 2015, 99, 197-209.	1.0	13
107	Reply to Thomason et al and Bahr et al. Clinical Infectious Diseases, 2015, 60, 1870-1871.	5.8	0
108	Ventilator-Associated Pneumonia (VAP) with Multidrug-Resistant (MDR) Pathogens: Optimal Treatment?. Current Infectious Disease Reports, 2015, 17, 494.	3.0	18

#	ARTICLE	IF	CITATIONS
109	Should Heparin Be Used to Treat Patients With Severe Sepsis?*. Critical Care Medicine, 2015, 43, 694-695.	0.9	3
110	Sepsis in the Severely Immunocompromised Patient. Current Infectious Disease Reports, 2015, 17, 487.	3.0	33
111	Administration of Brincidofovir and Convalescent Plasma in a Patient With Ebola Virus Disease. Clinical Infectious Diseases, 2015, 61, 969-973.	5.8	75
112	Is Bacteremic Sepsis Associated With Higher Mortality in Transplant Recipients Than in Nontransplant Patients? A Matched Case-Control Propensity-Adjusted Study. Clinical Infectious Diseases, 2015, 60, 216-222.	5.8	98
113	Does increasing immunoglobulin levels impact survival in solid organ transplant recipients with hypogammaglobulinemia?. Clinical Transplantation, 2014, 28, 1249-1255.	1.6	20
114	A Direct and Indirect Comparison Meta-Analysis on the Efficacy of Cytomegalovirus Preventive Strategies in Solid Organ Transplant. Clinical Infectious Diseases, 2014, 58, 785-803.	5.8	73
115	Therapeutic Hypothermia Is Cool, but Be Aware of the Infection Heat*. Critical Care Medicine, 2014, 42, 445-446.	0.9	2
116	The "Last Breath" of the Ventilator-Associated Pneumonia Surveillance Definition*. Critical Care Medicine, 2014, 42, 722-723.	0.9	4
117	Risk of serious opportunistic infections after solid organ transplantation: interleukin-2 receptor antagonists versus polyclonal antibodies. A meta-analysis. Expert Review of Anti-Infective Therapy, 2014, 12, 881-896.	4.4	6
118	Emerging and Resistant Infections. Annals of the American Thoracic Society, 2014, 11, S193-S200.	3.2	10
119	Association Between Vancomycin Minimum Inhibitory Concentration and Mortality Among Patients With <i>Staphylococcus aureus</i> Bloodstream Infections. JAMA - Journal of the American Medical Association, 2014, 312, 1552.	7.4	152
120	The complex link between influenza and severe sepsis. Virulence, 2014, 5, 137-142.	4.4	49
121	Bayesian Methodology for the Design and Interpretation of Clinical Trials in Critical Care Medicine. Critical Care Medicine, 2014, 42, 2267-2277.	0.9	33
122	Erratum for Gross et al., Epidemiology and Predictors of Multidrug-Resistant Community-Acquired and Health Care-Associated Pneumonia. Antimicrobial Agents and Chemotherapy, 2014, 58, 6342-6342.	3.2	1
123	Probiotics and antibiotic-associated diarrhoea. Lancet, The, 2014, 383, 29-30.	13.7	14
124	Quantitative versus qualitative cultures of respiratory secretions for clinical outcomes in patients with ventilator-associated pneumonia. The Cochrane Library, 2014, , CD006482.	2.8	88
125	Bayes' 250-year-old legacy for infectious diseases. Lancet Infectious Diseases, The, 2014, 14, 674-675.	9.1	0
126	Epidemiology and Predictors of Multidrug-Resistant Community-Acquired and Health Care-Associated Pneumonia. Antimicrobial Agents and Chemotherapy, 2014, 58, 5262-5268.	3.2	109

#	ARTICLE	IF	CITATIONS
127	An International Survey of Cytomegalovirus Prevention and Treatment Practices in Intestinal Transplantation. <i>Transplantation</i> , 2014, 97, 78-82.	1.0	27
128	Anti-inflammatory Effects of Rosuvastatin in Healthy Subjects: A Prospective Longitudinal Study. <i>Current Pharmaceutical Design</i> , 2014, 20, 1156-1160.	1.9	11
129	Treatment of hospital-acquired pneumonia with linezolid or vancomycin: a systematic review and meta-analysis. <i>BMJ Open</i> , 2013, 3, e003912.	1.9	61
130	Severe sepsis: are PROWESS and PROWESS-SHOCK trials comparable? A clinical and statistical heterogeneity analysis. <i>Critical Care</i> , 2013, 17, 167.	5.8	15
131	Cytomegalovirus reactivation and colitis after left ventricular assist device placement. <i>International Journal of Infectious Diseases</i> , 2013, 17, e348-e351.	3.3	8
132	Drotrecogin alfa (activated) in severe sepsis – Authors' reply. <i>Lancet Infectious Diseases</i> , The, 2013, 13, 110-111.	9.1	0
133	Blood Purification. <i>Critical Care Medicine</i> , 2013, 41, 2244-2245.	0.9	3
134	Deciphering the Sepsis Riddle. <i>Critical Care Medicine</i> , 2013, 41, 2458-2460.	0.9	8
135	Hospital-Acquired Pneumonia. <i>Critical Care Medicine</i> , 2013, 41, 2232-2233.	0.9	0
136	Effect of Eritoran, an Antagonist of MD2-TLR4, on Mortality in Patients With Severe Sepsis. <i>JAMA - Journal of the American Medical Association</i> , 2013, 309, 1154.	7.4	625
137	<i>Pediococcus acidilactici</i> Endocarditis Successfully Treated with Daptomycin. <i>Journal of Clinical Microbiology</i> , 2012, 50, 1106-1108.	3.9	10
138	Cytomegalovirus and mortality in critical care patients. <i>Critical Care Medicine</i> , 2012, 40, 303-305.	0.9	3
139	Risk Factors for Systemic Candida Infections in Pediatric Small Bowel Transplant Recipients. <i>Pediatric Infectious Disease Journal</i> , 2012, 31, 120-123.	2.0	20
140	Risk Factors and Outcomes of Staphylococcus aureus Infections After Small Bowel and Multivisceral Transplantation. <i>Pediatric Infectious Disease Journal</i> , 2012, 31, 25-29.	2.0	5
141	Bloodstream Infections During the First Year After Pediatric Small Bowel Transplantation. <i>Pediatric Infectious Disease Journal</i> , 2012, 31, 700-704.	2.0	45
142	Is the evidence for benefits from ventilator-associated pneumonia bundles reliable enough for implementation in a general hospital?*. <i>Critical Care Medicine</i> , 2012, 40, 348-350.	0.9	3
143	Can we predict cytomegalovirus reactivation in critically ill patients?*. <i>Critical Care Medicine</i> , 2012, 40, 3313-3314.	0.9	1
144	Risk of cytomegalovirus disease in high-risk liver transplant recipients on valganciclovir prophylaxis: A systematic review and meta-analysis. <i>Liver Transplantation</i> , 2012, 18, 1440-1447.	2.4	28

#	ARTICLE	IF	CITATIONS
145	<i>Staphylococcus aureus</i> infections in kidney transplantation: A matched case controlled study. Scandinavian Journal of Infectious Diseases, 2012, 44, 427-432.	1.5	13
146	Effectiveness and safety of drotrecogin alfa (activated) for severe sepsis: a meta-analysis and metaregression. Lancet Infectious Diseases, The, 2012, 12, 678-686.	9.1	73
147	Should Multivisceral Transplantation Be Considered in Patients Colonized with Multidrug-Resistant <i>Pseudomonas aeruginosa</i> ?. Microbial Drug Resistance, 2012, 18, 74-78.	2.0	4
148	Respiratory syncytial virus lower respiratory tract infection in a pediatric liver transplant recipient treated with oral ribavirin. Pediatric Transplantation, 2012, 16, E348-51.	1.0	9
149	Evaluation of an Infrared Thermal Detection System for Fever Recognition during the H1N1 Influenza Pandemic. Infection Control and Hospital Epidemiology, 2011, 32, 504-506.	1.8	30
150	Is cytomegalovirus reactivation increasing the mortality of patients with severe sepsis?. Critical Care, 2011, 15, 138.	5.8	24
151	Is it time to replace l-arginine in severe sepsis?*. Critical Care Medicine, 2011, 39, 417-418.	0.9	3
152	Influence of Severity of Illness on the Effects of Eritoran Tetrasodium (E5564) and on Other Therapies for Severe Sepsis. Shock, 2011, 36, 327-331.	2.1	33
153	Why Valganciclovir Should Not Be Indicated for Liver Recipients and High-Dose Acyclovir Should Not Be Removed From International Cytomegalovirus Guidelines. Transplantation, 2011, 91, e8-e9.	1.0	3
154	Linezolid does not show advantages over vancomycin in modulating the pulmonary immune response: How should we conciliate these new findings with the Zephyr trial results?*. Critical Care Medicine, 2011, 39, 2009-2010.	0.9	2
155	Is there a role for oral human immunoglobulin in the treatment for norovirus enteritis in immunocompromised patients?. Pediatric Transplantation, 2011, 15, 718-721.	1.0	65
156	IMPACT Trial Results Should Not Change Current Standard of Care of 100 Days for Cytomegalovirus Prophylaxis. American Journal of Transplantation, 2011, 11, 18-21.	4.7	16
157	Low-dose steroids for septic shock and severe sepsis: the use of Bayesian statistics to resolve clinical trial controversies. Intensive Care Medicine, 2011, 37, 420-429.	8.2	55
158	Reply to Sprung et al: steroid treatment for patients with severe sepsis and septic shock. Intensive Care Medicine, 2011, 37, 1567-1568.	8.2	0
159	Cytomegalovirus Infections in Non-Immunocompromised and Immunocompromised Patients in the Intensive Care Unit. Infectious Disorders - Drug Targets, 2011, 11, 354-364.	0.8	29
160	Is cefepime safe for clinical use? A Bayesian viewpoint. Journal of Antimicrobial Chemotherapy, 2011, 66, 1207-1209.	3.0	22
161	Effectiveness of Valganciclovir 900 mg versus 450 mg for Cytomegalovirus Prophylaxis in Transplantation: Direct and Indirect Treatment Comparison Meta-analysis. Clinical Infectious Diseases, 2011, 52, 313-321.	5.8	57
162	Linezolid versus vancomycin or teicoplanin for nosocomial pneumonia: A systematic review and meta-analysis*. Critical Care Medicine, 2010, 38, 1802-1808.	0.9	122

#	ARTICLE	IF	CITATIONS
163	Does recombinant activated protein C work in patients with severe sepsis?*. Critical Care Medicine, 2010, 38, 1217-1220.	0.9	5
164	Candida albicans Skin Abscess in a Heart Transplant Recipient. Infectious Diseases in Clinical Practice, 2010, 18, 243-246.	0.3	3
165	Identifying Predictors of Central Nervous System Disease in Solid Organ Transplant Recipients With Cryptococcosis. Transplantation, 2010, 89, 69-74.	1.0	28
166	The importance of detecting cytomegalovirus infections in studies evaluating new therapies for severe sepsis. Critical Care Medicine, 2010, 38, S663-S667.	0.9	8
167	Adenovirus Infections in Pediatric Small Bowel Transplant Recipients. Transplantation, 2010, 90, 198-204.	1.0	64
168	Wanted: early goal-directed therapy for septic shock—dead or alive, but not critically ill!. Intensive Care Medicine, 2010, 36, 1-3.	8.2	4
169	Recommendations for the Assessment and Reporting of Multivariable Logistic Regression in Transplantation Literature. American Journal of Transplantation, 2010, 10, 1695-1703.	4.7	46
170	Unrecognized Pretransplant and Donor-Derived Cryptococcal Disease in Organ Transplant Recipients. Clinical Infectious Diseases, 2010, 51, 1062-1069.	5.8	80
171	Positive Deviance and Hand Hygiene: More Questions than Answers. Infection Control and Hospital Epidemiology, 2010, 31, 978-979.	1.8	2
172	Geographic differences in disease expression of cryptococcosis in solid organ transplant recipients in the United States. Annals of Transplantation, 2010, 15, 77-83.	0.9	7
173	Valganciclovir for Cytomegalovirus Prevention in Solid Organ Transplant Patients: An Evidence-Based Reassessment of Safety and Efficacy. PLoS ONE, 2009, 4, e5512.	2.5	74
174	Can Serum Mannose-Binding Lectin Levels Aid with the Diagnosis of Invasive Aspergillosis?. Clinical Infectious Diseases, 2009, 49, 1492-1495.	5.8	2
175	Lipid Formulations of Amphotericin B Significantly Improve Outcome in Solid Organ Transplant Recipients with Central Nervous System Cryptococcosis. Clinical Infectious Diseases, 2009, 49, 1721-1728.	5.8	57
176	Cerebral aspergillosis caused by <i>Aspergillus ustus</i> following orthotopic heart transplantation: case report and review of the literature. Clinical Transplantation, 2009, 23, 116-120.	1.6	16
177	Evaluation of the coagulation and inflammatory responses in solid organ transplant recipients and donors. Clinical Transplantation, 2009, 23, 943-950.	1.6	16
178	Misguided guidelines on noninvasive thermometry. Critical Care Medicine, 2009, 37, 383-384.	0.9	2
179	Prevalence and mortality associated with cytomegalovirus infection in nonimmunosuppressed patients in the intensive care unit*. Critical Care Medicine, 2009, 37, 2350-2358.	0.9	198
180	Cytomegalovirus viremia in solid organ transplantation: does the initial viral load correlate with risk factors and outcomes?. Clinical Transplantation, 2008, 22, 222-228.	1.6	24

#	ARTICLE	IF	CITATIONS
181	How many patients with severe sepsis are needed to confirm the efficacy of drotrecogin alfa activated? A Bayesian design. <i>Intensive Care Medicine</i> , 2008, 34, 1804-1811.	8.2	9
182	Quantitative versus qualitative cultures of respiratory secretions for clinical outcomes in patients with ventilator-associated pneumonia. , 2008, , CD006482.		20
183	Pulmonary Cryptococcosis in Solid Organ Transplant Recipients: Clinical Relevance of Serum Cryptococcal Antigen. <i>Clinical Infectious Diseases</i> , 2008, 46, e12-e18.	5.8	163
184	Calcineurin Inhibitor Agents Interact Synergistically with Antifungal Agents In Vitro against <i>Cryptococcus neoformans</i> Isolates: Correlation with Outcome in Solid Organ Transplant Recipients with Cryptococcosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 735-738.	3.2	91
185	Meta-analysis under the spotlight: We must differentiate its limitations versus its prejudices. <i>Critical Care Medicine</i> , 2008, 36, 3124-3126.	0.9	4
186	A silent killer: Cytomegalovirus infection in the nonimmunocompromised critically ill patient*. <i>Critical Care Medicine</i> , 2008, 36, 3261-3264.	0.9	19
187	Diagnosis of pneumonia in the critically ill patient: Is it time to abandon bronchoscopy?*. <i>Critical Care Medicine</i> , 2008, 36, 344-345.	0.9	2
188	Guidelines for evaluation of new fever in critically ill adult patients: 2008 update from the American College of Critical Care Medicine and the Infectious Diseases Society of America. <i>Critical Care Medicine</i> , 2008, 36, 1330-1349.	0.9	549
189	Why Are Clinicians Not Embracing the Results from Pivotal Clinical Trials in Severe Sepsis? A Bayesian Analysis. <i>PLoS ONE</i> , 2008, 3, e2291.	2.5	35
190	Sepsis and Solid Organ Transplantation. <i>Current Drug Targets</i> , 2007, 8, 533-541.	2.1	64
191	Strategies To Prevent Organ Disease by Cytomegalovirus in Solid Organ Transplant Recipients. <i>Annals of Internal Medicine</i> , 2006, 144, 457.	3.9	0
192	L-Arginine supplementation in sepsis: beneficial or harmful?. <i>Current Opinion in Critical Care</i> , 2006, 12, 303-308.	3.2	43
193	Preclinical trial of l-arginine monotherapy alone or with N-acetylcysteine in septic shock*. <i>Critical Care Medicine</i> , 2006, 34, 2719-2728.	0.9	70
194	Controlling the Troll. <i>Annals of Internal Medicine</i> , 2006, 144, 457.	3.9	0
195	Antifungal Management Practices and Evolution of Infection in Organ Transplant Recipients with <i>Cryptococcus Neoformans</i> Infection. <i>Transplantation</i> , 2005, 80, 1033-1039.	1.0	70
196	Meta-Analysis: The Efficacy of Strategies To Prevent Organ Disease by Cytomegalovirus in Solid Organ Transplant Recipients. <i>Annals of Internal Medicine</i> , 2005, 143, 870.	3.9	344
197	Neutrophil inhibition with L-selectin-directed MAb improves or worsens survival dependent on the route but not severity of infection in a rat sepsis model. <i>Journal of Applied Physiology</i> , 2005, 98, 2155-2162.	2.5	17
198	The Use of Dexamethasone in Bacterial Meningitis. <i>Clinical Infectious Diseases</i> , 2005, 40, 1061-1062.	5.8	3

#	ARTICLE	IF	CITATIONS
199	Use of Interferon- α in Patients with West Nile Encephalitis: Report of 2 Cases. <i>Clinical Infectious Diseases</i> , 2005, 40, 764-766.	5.8	95
200	An Immune Reconstitution Syndrome-Like Illness Associated with <i>Cryptococcus neoformans</i> Infection in Organ Transplant Recipients. <i>Clinical Infectious Diseases</i> , 2005, 40, 1756-1761.	5.8	243
201	Safety, Pharmacokinetics, and Pharmacodynamics of Drotrecogin Alfa (Activated) in Children With Severe Sepsis. <i>Pediatrics</i> , 2004, 113, 7-17.	2.1	133
202	West Nile Virus-Associated Encephalitis in Recipients of Renal and Pancreas Transplants: Case Series and Literature Review. <i>Clinical Infectious Diseases</i> , 2004, 38, 1257-1260.	5.8	85
203	Unresolved Questions With the Use of Linezolid vs Vancomycin for Nosocomial Pneumonia. <i>Chest</i> , 2004, 125, 2370-2371.	0.8	38
204	Effects of Drotrecogin Alfa (Activated) in Human Endotoxemia. <i>Shock</i> , 2004, 21, 222-229.	2.1	84
205	Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial*. <i>Critical Care Medicine</i> , 2003, 31, 834-840.	0.9	359
206	Risk and the Efficacy of Antiinflammatory Agents. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2002, 166, 1197-1205.	5.6	344
207	Infections in Small Bowel Transplant Recipients. , 0, , 297-304.		1